Further, evidence suggests that in cancer, tumor epitope-specific T cells are preferentially eliminated either directly via the Fas/FasL or Trail/TRAILR pathways (Albers et al., 2006) or indirectly through the release of tumor-derived exosomes (TEX) carrying death receptor ligands (Kim et al., 2005b). Here, FAS is linked to neoplasm.